The Royal Marsden NHS Foundation Trust

Automata Technologies: Joe Stringer appointed Executive Chairman & Director of Corporate Development (EMEA)

Retrieved on: 
Monday, November 6, 2023

Automata Technologies (‘Automata’ or the ‘Company’), a leading automation company powering life sciences labs, has appointed Joe Stringer Executive Chairman and Director of Corporate Development for the UK and EMEA.

Key Points: 
  • Automata Technologies (‘Automata’ or the ‘Company’), a leading automation company powering life sciences labs, has appointed Joe Stringer Executive Chairman and Director of Corporate Development for the UK and EMEA.
  • Joe joins Automata from Octopus Ventures where he was most recently Head of Healthtech Investments.
  • Through his role at Octopus Ventures, Joe has been involved with Automata since January 2022 as an investor and Investor Director, and remains on the Board of Directors.
  • Mostafa Elsayed, Founder and CEO of Automata, commented:
    "It is great to welcome Joe to the Automata family full-time.

Volition Presents Breakthrough Liquid Biopsy Blood Test Method for Early-stage Cancer

Retrieved on: 
Monday, October 23, 2023

Volition has developed a novel method for liquid biopsy involving the first reported physical isolation of a class of tumor-derived ctDNA fragments from blood.

Key Points: 
  • Volition has developed a novel method for liquid biopsy involving the first reported physical isolation of a class of tumor-derived ctDNA fragments from blood.
  • Removal of normal DNA obviates expensive and time-consuming DNA sequencing and bioinformatics allowing for rapid, cost-effective detection in a routine blood test."
  • Volition tested the new method in a first small clinical experiment and detected a range of liquid and other cancers, including at early stage I disease.
  • Volition has organized a data insights webinar on Thursday 26th October at 10.30 AM U.S. Eastern to provide more information about the new cancer detection method.

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023

Retrieved on: 
Monday, October 23, 2023

The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.

Key Points: 
  • The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.
  • As of the data cut-off on 8 September 2023, the trial had enrolled 23 heavily pre-treated patients across various tumor types where HER3 may play an important role.
  • The dose escalation trial cleared six monotherapy cohorts with no dose-limiting toxicities (DLTs) and there were no treatment discontinuations due to related adverse events.
  • " The Phase I/IIa clinical trial in the UK is sponsored and managed by Cancer Research UK's Centre for Drug Development.

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023

Retrieved on: 
Monday, October 23, 2023

The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.

Key Points: 
  • The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.
  • As of the data cut-off on 8 September 2023, the trial had enrolled 23 heavily pre-treated patients across various tumor types where HER3 may play an important role.
  • The dose escalation trial cleared six monotherapy cohorts with no dose-limiting toxicities (DLTs) and there were no treatment discontinuations due to related adverse events.
  • " The Phase I/IIa clinical trial in the UK is sponsored and managed by Cancer Research UK's Centre for Drug Development.

Automata Technologies: $40m fundraise backed by Dimension and A.P. Moller Holding, to expand growing life science lab automation offering

Retrieved on: 
Tuesday, October 3, 2023

This is happening at the same time as they struggle to find laboratory real estate as well as finding and retaining skilled lab staff.

Key Points: 
  • This is happening at the same time as they struggle to find laboratory real estate as well as finding and retaining skilled lab staff.
  • This convergence is leading to organisations rethinking their tooling, data infrastructure and ability to experiment at scale.
  • Moller Holding, added:
    ““We are delighted to partner with Automata, an emerging leader in modernizing and automating the global life science industry.
  • Automata’s solutions help increase throughput, lower cost, and accelerate innovation allowing its customers to focus on pushing further into cutting edge medical and life science research.”

Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit

Retrieved on: 
Thursday, September 28, 2023

Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the presentation of scientific background and clinical trial updates on the avutometinib and defactinib programs at the 5th Annual RAS-Targeted Drug Development Summit in Boston, Massachusetts.

Key Points: 
  • Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the presentation of scientific background and clinical trial updates on the avutometinib and defactinib programs at the 5th Annual RAS-Targeted Drug Development Summit in Boston, Massachusetts.
  • The updates are part of two oral presentations by Jonathan Pachter, PhD, Chief Scientific Officer and Louis Denis, MD, Chief Medical Officer at Verastem Oncology.
  • The first presentation titled “Vertical Inhibition of RAS, RAF & MEK: Enhancing Antitumor Efficacy of KRAS G12C & G12D Inhibitors with RAF/MEK Clamp Avutometinib”, includes scientific rationale for clinical combinations with avutometinib and defactinib in various RAS pathway-driven cancers.
  • The second presentation titled, “Introducing Rational Combinations of RAF/MEK Clamp Avutometinib: Breakthrough Therapy Designation & Beyond,” discusses novel combination treatment approaches and provides an overview of the avutometinib and defactinib clinical development program.

GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research - MRFF Grant names GTG as sole Industry Partner

Retrieved on: 
Monday, September 11, 2023

The grant will provide funding for the CASSOWARY Trial: a randomised controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice.

Key Points: 
  • The grant will provide funding for the CASSOWARY Trial: a randomised controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice.
  • GTG is the National Research Partner for trial which is to be led by Professor Jon Emery.
  • The trial results will inform future policy including the 5-year goal in the Australian Cancer Plan of using genomics for risk-stratified cancer screening.
  • As the sole industry partner, GTG will receive funding to cover the supply of test kits and the analysis of the sample returned.

New Appointments Expand Strategic Capability and Reach of the CEO Leadership Alliance Orange County Board of Directors

Retrieved on: 
Friday, August 11, 2023

IRVINE, Calif., Aug. 11th, 2023 /PRNewswire-PRWeb/ -- CEO Leadership Alliance Orange County (CLAOC) today announced the appointment of five new members to its Board of Directors. This expansion and formalization of the organization's non-profit board will allow CLAOC to further scale its work and increase its impact as a force to build a thriving OC for all by developing skilled talent ready to take on innovation jobs.

Key Points: 
  • CEO Leadership Alliance Orange County (CLAOC) today announced the appointment of five new members to its Board of Directors.
  • IRVINE, Calif., Aug. 11th, 2023 /PRNewswire-PRWeb/ -- CEO Leadership Alliance Orange County (CLAOC) today announced the appointment of five new members to its Board of Directors.
  • The five incoming board members are:
    Darryl Button, President and CEO, Pacific Life Insurance Company – Named CEO in 2022, Darryl joined Pacific Life in 2017 as executive vice president and CFO.
  • "Welcome to our new board members," says Annette Walker, President, City of Hope, and CLAOC Board of Directors.

AccuStem Sciences, Inc. Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer

Retrieved on: 
Tuesday, July 11, 2023

This important milestone will support the company’s strategic vision following positive results from transATAC study where StemPrintER assay outperformed the current market leader in risk of recurrence testing for women with early stage breast cancer.

Key Points: 
  • This important milestone will support the company’s strategic vision following positive results from transATAC study where StemPrintER assay outperformed the current market leader in risk of recurrence testing for women with early stage breast cancer.
  • Beyond this agreement, AccuStem intends to work closely with the IEO on additional proprietary cancer assays leveraging StemPrintER technology.
  • The pivotal TransATAC study has been used to evaluate many of the commonly used breast cancer risk scoring assays, including the market leading OncotypeDX.
  • AccuStem plans to launch clinical studies to evaluate StemPrintER’s ability to determine the most effective surgical approach for women with early stage invasive breast cancer.

Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas

Retrieved on: 
Saturday, June 3, 2023

WESTPORT, Conn., June 3, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral (IT) cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that data from its ongoing phase 1/2 clinical trial demonstrating the efficacy and tolerability of INT230-6, either as monotherapy or in combination with ipilimumab in patients with relapsed, refractory and metastatic sarcomas, will be presented this afternoon at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago and virtually from June 2-6, 2023.

Key Points: 
  • Abstract Title: Intratumoral INT230-6 (Cisplatin, Vinblastine, SHAO) alone or with ipilimumab (IPI) prolonged survival with favorable safety in adults with refractory sarcomas [Intensity IT-01; BMS#CA184-592].
  • Sarcoma remains a very challenging cancer to treat and has historically proven resistant to checkpoint blockade.
  • Novel approaches are needed for this patient population, and Intensity's data indicate that sarcoma is an attractive target for intratumoral injection.
  • For the combination arm, one subject had yet to reach the first timepoint for SD at the time of data cut-off.